Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol/melitracen is a fixed-dose combination psychotropic agent. Flupentixol is a thioxanthene neuroleptic (antipsychotic) with anxiolytic and antidepressant properties at low doses. Melitracen is a tricyclic antidepressant (TCA). The combination is used to treat mild to moderate anxiety, depression, and apathy. It is not approved by the FDA or EMA; availability is primarily limited to specific international markets (e.g., Deanxit).
## Primary Indications
* Psychogenic depression
* Depressive neuroses
* Masked depression
* Psychosomatic affections accompanied by anxiety and apathy
## Adult Dosing
* **Initial Dose:** 1 tablet twice daily (morning and noon).
* **Maintenance:** 1 tablet daily (morning).
* **Severe cases:** May increase to 2 tablets in the morning and 1 tablet at noon.
* **Maximum Dose:** 4 tablets per day.
* *Note: Due to the long half-life of melitracen, avoid evening dosing to prevent insomnia.*
## Pediatric Dosing
* **Established Dosing:** Not established.
* **Usage:** Generally not recommended for children or adolescents due to lack of safety/efficacy data and the potential for cardiovascular/neurological side effects associated with TCAs and neuroleptics.
## Dose Adjustments
* **Renal/Hepatic Impairment:** Specific dose adjustments are not standardized. Use with extreme caution; monitor for increased drug levels due to potential decreased clearance.
* **Elderly:** Use lowest effective dose; start with 1 tablet once daily in the morning. Increased risk of anticholinergic effects, hypotension, and EPS.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or excipients.
* Recent myocardial infarction.
* Cardiac conduction defects (e.g., heart block, prolongation of QT interval).
* Untreated narrow-angle glaucoma.
* Acute alcohol, barbiturate, or opioid intoxication.
* Concomitant use with MAO inhibitors (must have a 14-day washout period).
* Blood dyscrasias.
## Adverse Effects
* **Common:** Dry mouth, insomnia, dizziness, restlessness, tremor, constipation.
* **Serious:** Extrapyramidal symptoms (EPS), tardive dyskinesia, orthostatic hypotension, cardiac arrhythmias (QT prolongation), seizures, urinary retention, and agranulocytosis.
## Key Drug Interactions
* **MAO Inhibitors:** Severe hypertensive crisis or serotonin syndrome risk.
* **CNS Depressants:** Enhanced sedative effects if combined with alcohol, opioids, or benzodiazepines.
* **Antihypertensives:** Potential for additive hypotensive effects.
* **QT Prolonging Agents:** Increased risk of life-threatening arrhythmias (e.g., macrolides, fluoroquinolones, other antipsychotics).
* **Anticholinergics:** Exacerbation of dry mouth, urinary retention, and confusion.
## Monitoring
* **Baseline:** ECG (especially in patients with cardiac risk factors), baseline CBC, and liver function tests.
* **Ongoing:** Monitor for EPS (involuntary movements), signs of cardiac conduction changes, and orthostatic blood pressure. Evaluate patient for suicidal ideation, especially during initial therapy.
## Clinical Pearls
* **Timing:** Due to the stimulating effect, avoid doses after 4 PM to prevent sleep disruption.
* **Dependency:** Potential for dependence or misuse exists; monitor for signs of diversion or abuse.
* **Withdrawal:** Abrupt cessation may cause withdrawal symptoms. Taper slowly after long-term use.
* **Regulation:** This combination is not recognized by major regulatory bodies (FDA, EMA) and is unavailable in many countries. Prescribers should adhere to local clinical guidelines where the drug is authorized.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug availability, indications, and dosing protocols vary significantly by country and local clinical guidelines. Always consult current, localized prescribing information, product monographs, or a licensed pharmacist before making clinical decisions.
